# CORRESP — Akari Therapeutics Plc  (AKTX)  (CIK 0001541157)

> <strong>Akari Therapeutics Plc  (AKTX)  (CIK 0001541157) → SEC staff</strong> · filed 2025-12-01 · ticker AKTX · SIC 2834

## What is this

A CORRESP letter is the company's written reply to the SEC during a filing review. Responses include accounting position arguments, restatement assessments, and clarifying disclosures. Released to EDGAR alongside the SEC's UPLOAD letters.

## Key facts

- **Accession number:** 0001493152-25-025537
- **Form:** CORRESP
- **Filer:** Akari Therapeutics Plc  (AKTX)  (CIK 0001541157)
- **CIK:** 0001541157
- **Ticker:** AKTX
- **Filed:** 2025-12-01
- **SIC industry:** 2834
- **HQ:** Tampa, FL

## Primary source

PDF letter: https://www.sec.gov/Archives/edgar/data/1541157/000149315225025537/filename1.htm

EDGAR review history for this filer: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1541157&type=UPLOAD&dateb=&owner=include&count=40

## Other comment-letter activity for Akari Therapeutics Plc  (AKTX)  (CIK 0001541157)

- UPLOAD — 2026-01-27 — /comment-letter/0000000000-26-000815
- CORRESP — 2026-01-27 — /comment-letter/0001493152-26-003763

## Citation

> US Securities and Exchange Commission, EDGAR CORRESP comment letter, Akari Therapeutics Plc  (AKTX)  (CIK 0001541157) (CIK 0001541157), filed 2025-12-01, accession 0001493152-25-025537. Retrieved via MORVS 2026-11-04 from https://api.morvs.ai/comment-letter/0001493152-25-025537.

---

*[SEC comment letters dataset](/datasets/sec-comment-letters) · CC0 1.0*